1 not yet recruiting, 1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow 177Lu-TLX250: new trials by email Literature Review of 177Lu-TLX250 trials Research Report on 177Lu-TLX250
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-03-25 | 2026-04-01 |
Carcinoma, Renal Cell (2) · Kidney Neoplasms (2) · Recurrence (2)
Telix Pharmaceuticals (Innovations) Pty Limited (2)
Australia (1) · United States (1)
2025 (1)